) The Microarray Core provides a centralized resource for services, materials and equipment required for performing large-scale gene expression studies utilizing cDNA and oligonucleotide-based microarrays. Microarray technology has developed at a rapid pace; however, the high cost burden of the instrumentation and biological resources makes the technology too expensive for most laboratories. Since microarray analysis is broadly applicable across all areas of research represented at the Cancer Center, the Microarray Core Facility is a logical mechanism to provide access to this powerful technology. By combining microarray resources into a shared facility, it is possible for all research programs within the Center to conduct gene expression profiling studies. In addition to making microarray technology generally available, providing microarray services through a shared resource has additional benefits relating to applications development. From the total annual operating cost of $479,465, we are requesting $66,336 from the CCSG allocation, an amount that represents approximately 14 percent of the total operating budget. These funds will support a portion of Facility staff salaries and service contracts.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA076292-04
Application #
6492401
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
1998-02-19
Project End
2006-01-31
Budget Start
Budget End
Support Year
4
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of South Florida
Department
Type
DUNS #
City
Tampa
State
FL
Country
United States
Zip Code
33612
Karolak, Aleksandra; Markov, Dmitry A; McCawley, Lisa J et al. (2018) Towards personalized computational oncology: from spatial models of tumour spheroids, to organoids, to tissues. J R Soc Interface 15:
Liu, Ying; Wang, Hua; Li, Qian et al. (2018) Radiologic Features of Small Pulmonary Nodules and Lung Cancer Risk in the National Lung Screening Trial: A Nested Case-Control Study. Radiology 286:298-306
Padron, Eric; Ball, Markus C; Teer, Jamie K et al. (2018) Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes. Blood 131:2402-2405
Verduzco, Daniel; Kuenzi, Brent M; Kinose, Fumi et al. (2018) Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines. Mol Cancer Ther 17:73-83
Lee, Morgan S; Tyson, Dinorah Martinez; Gonzalez, Brian D et al. (2018) Anxiety and depression in Spanish-speaking Latina cancer patients prior to starting chemotherapy. Psychooncology 27:333-338
Correa, John B; Brandon, Karen O; Meltzer, Lauren R et al. (2018) Electronic cigarette use among patients with cancer: Reasons for use, beliefs, and patient-provider communication. Psychooncology 27:1757-1764
Divakaran, Anand; Talluri, Siva K; Ayoub, Alex M et al. (2018) Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor. J Med Chem 61:9316-9334
de Mingo Pulido, Álvaro; Gardner, Alycia; Hiebler, Shandi et al. (2018) TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. Cancer Cell 33:60-74.e6
Li, Gongbo; Boucher, Justin C; Kotani, Hiroshi et al. (2018) 4-1BB enhancement of CAR T function requires NF-?B and TRAFs. JCI Insight 3:
McIntyre, Jessica; Jiménez, Julio; Rivera, Yonaira M et al. (2018) Comparison of Health Communication Channels for Reaching Hispanics About Biobanking: a Pilot Trial. J Cancer Educ 33:833-841

Showing the most recent 10 out of 1254 publications